VXS-1223

VXS-1223 is an investigational COVID-19 booster vaccine developed by Vaxxas. It consists of a stabilized, prefusion form of the SARS-CoV-2 spike protein subunit antigen (HexaPro), which is licensed from the University of Texas at Austin and the National Institutes of Health (NIH). Rather than conventional needle injection, VXS-1223 is delivered intradermally using Vaxxas' proprietary High-Density Microarray Patch (HD-MAP) technology, a needle-free, room-temperature-stable patch applicator. The vaccine is designed to elicit a robust immune response by targeting the high density of immune cells directly beneath the skin surface. VXS-1223 has completed a randomized, placebo-controlled, blinded Phase 1 clinical trial in Australia evaluating its safety, tolerability, and immunogenicity as a booster in healthy adults previously vaccinated with three doses of a COVID-19 vaccine.